Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Danaher Corp.
DHRHealthcareGenerated Aug 19, 2026, 10:32 PM UTC
DHR (Danaher Corp.) analytical snapshot. Revenue grew +2.9% YoY to $24.57B. 5-year revenue CAGR -3.6%; 10y CAGR +4.3%. Net margin at 14.71% (contracting ▼). Market cap $148.68B at $211.50 per share. Trailing P/E 41.88, P/S 6.05, P/B 2.83. EV/Operating income ≈ 36.15 (EV $169.55B). Risk: Low. Macro: Risk-on · Supportive. Composite analytical score 1 (data confidence 84%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 24, 2026. Latest quarterly report (10-Q) filed Jul 21, 2026. 11 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 24, 2026.
- Latest quarterly report (10-Q) filed Jul 21, 2026.
- 11 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Danaher Corp.; broad institutional reporting.
- Recent filers include Aldebaran Financial Inc., INVESTORS TRUST CO /PA, Gardiner Nancy B.
- 20 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| Aldebaran Financial Inc. | 13F-HR | Aug 14, 2015 |
| INVESTORS TRUST CO /PA | 13F-HR | Feb 15, 2002 |
| Gardiner Nancy B | 13F-HR | Jul 26, 2017 |
| Fayerweather Charles | 13F-HR | Oct 26, 2017 |
| Saranac Partners Ltd | 13F-HR | Dec 5, 2025 |
| Date | Form | Description |
|---|---|---|
| Aug 3, 2026 | 8-K | 8-K |
| Jul 21, 2026 | 8-K | 8-K |
| Jun 3, 2026 | 8-K | 8-K |
| May 7, 2026 | 8-K | 8-K |
| Apr 29, 2026 | 8-K | 8-K |
| Apr 21, 2026 | 8-K | 8-K |
| Apr 17, 2026 | 8-K | 8-K |
| Feb 17, 2026 | 8-K | 8-K |
SEC Filing Deep-Analysis
1 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- Operating cash flow exceeds net income: OCF is 1.78x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Goodwill is 51% of total assets: Goodwill of $47.41B represents a large share of the balance sheet. If acquired businesses underperform, a non-cash impairment charge could materially impact earnings. Monitor segment performance and acquisition integration metrics.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 1 new risk-language term(s) detected in filing text: Off-balance sheet arrangements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $23.88B | $24.57B | $693.0M | +2.9% |
| Gross profit | $14.21B | $14.52B | $317.0M | +2.2% |
| Operating income | $4.86B | $4.69B | $-173.0M | -3.6% |
| Net income | $3.90B | $3.61B | $-285.0M | -7.3% |
| Operating cash flow | $6.69B | $6.42B | $-272.0M | -4.1% |
| Capex | $1.39B | $1.16B | $-236.0M | -17.0% |
| Total assets | $77.54B | $83.46B | $5.92B | +7.6% |
| Total liabilities | $7.97B | $8.44B | $479.2M | +6.0% |
| Long-term debt | $16.00B | $18.42B | $2.41B | +15.1% |
| Cash & equivalents | $2.08B | $4.62B | $2.54B | +122.1% |
| Stockholders equity | $49.54B | $52.53B | $2.99B | +6.0% |
| Inventory | $2.33B | $2.49B | $159.0M | +6.8% |
| Accounts receivable | $3.54B | $3.91B | $376.0M | +10.6% |
| R&D expense | $1.58B | $1.60B | $14.0M | +0.9% |
| SG&A expense | $7.76B | $8.23B | $476.0M | +6.1% |
| Interest expense | $211.0M | $286.0M | $75.0M | +35.5% |
| Type | Concepts |
|---|---|
| Added | DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent |
| Removed | AccrualForEnvironmentalLossContingencies, AccruedEnvironmentalLossContingenciesNoncurrent, AccruedIncomeTaxesCurrent, AccruedIncomeTaxesNoncurrent, BusinessAcquisitionProFormaEarningsPerShareDiluted, BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareDiluted, BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax, BusinessAcquisitionsProFormaNetIncomeLoss, BusinessAcquisitionsProFormaRevenue, CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Impairment charge | medium | 5 | 5 | Ongoing |
| Restructuring | medium | 5 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 0 | NEW |
| Related party transactions | low | 5 | 0 | NEW |
Fundamentals
Revenue grew +2.9% YoY to $24.57B. 5-year revenue CAGR -3.6%; 10y CAGR +4.3%. Net margin at 14.71% (contracting ▼).
- Revenue grew +2.9% YoY to $24.57B.
- 5-year revenue CAGR -3.6%; 10y CAGR +4.3%.
- Net margin at 14.71% (contracting ▼).
- Return on equity 6.88%, ROA 4.33%, ROIC 6.61%.
- Gross margin 59.11%, operating margin 19.09%.
- Free cash flow margin 21.41% ($5.26B).
- Net income down ▼ +7.3% YoY.
- Debt/equity 0.51, current ratio 1.65, net debt $20.87B.
- Asset turnover 0.27 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $23.88B | -0.1% | 59.50 | 20.37 | 16.33 | $5.30B | 7.87 |
| 2025 | $24.57B | +2.9% | 59.11 | 19.09 | 14.71 | $5.26B | 6.88 |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $148.68B at $211.50 per share. Trailing P/E 41.88, P/S 6.05, P/B 2.83. EV/Operating income ≈ 36.15 (EV $169.55B).
- Market cap $148.68B at $211.50 per share.
Price & Technicals
Price $211.50 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 67.79.
- Price $211.50 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Low. Leverage debt/equity 0.51 (moderate). Liquidity current ratio 1.65 (adequate).
- Composite risk: Low.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite 1
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Danaher Corp. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewPrice $211.50 — uptrend (above 200-DMA); 1-month momentum positive..
Peer comparison
Defensive groupHow DHR stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 19 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR● you | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Walmart Inc. WMT | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |